Kenox Pharmaceuticals Inc., a company dedicated to developing innovative Orally Inhaled and Nasal Drug Products (OINDPs), has added small-scale non-sterile GMP capabilities to support GLP pre-clinical studies to its suite of drug development services.

This strategic expansion underscores Kenox’s commitment to accelerating the journey from molecule to clinic, providing its partners with the tools and expertise needed to bring life-changing therapies to market faster.

The new capabilities include a clean room for compounding, fill-finish and release of non-sterile nasal sprays, and dry powders. In addition, Kenox is working on further expansion to enable small scale GMP batch manufacturing for clinical trials (Phase I and II) of both non-sterile and sterile OINDPs. These new capabilities will streamline and de-risk the early stages of drug development for Kenox partners/clients thereby providing a one-stop-shop from the molecule to the clinic.

“I’m so excited about this expansion which was executed in a timely manner. This would not have been possible without our talented and capable team, rockstar QA, support from our partners/clients, various vendors, and the facility management,” said Sitaram Velaga, Founder, President and CEO at Kenox Pharmaceuticals Inc. “This expansion reflects our dedication to support our partners in their mission to develop cutting edge therapeutics for unmet medical needs with meticulous attention to quality, efficiency, project goals, and timelines.”

With these new capabilities, Kenox Pharmaceuticals Inc. is poised to support a diverse range of OINDP dosage forms intended for different therapeutic areas, including but not limited to cardiology, psychiatry, antimicrobial/antiviral, pain management and rare diseases.